WASHINGTON D.C. – Matrix Global Advisors (MGA) released a white paper that highlights how patent thickets increase barriers for American patients to access affordable biosimilar medications and treatments.  The paper explains how some biologic manufacturers prevent competition by creating patent walls with “overlapping, weaker” patents to significantly extend their drug’s monopoly and increase profits while limiting access to […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Releases Statement after AbbVie CEO Testifies Before the House Oversight and Reform Committee on Use of Anti-Competitive Tactics that Keep Drug Prices High: “CAPA applauds the Committee for its continued oversight on specific anti-competitive tactics that some big drug companies have engaged in over recent years. This patent gamesmanship […]

Continue Reading

WASHINGTON D.C. – The Coalition Against Patent Abuse (CAPA) released the following statement today after the House Committee on Oversight and Reform held a hearing entitled, “Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez,” that focuses on the company’s anti-competitive tactics and pricing strategies that keeps drug prices high for the American healthcare system and […]

Continue Reading

This Report Comes as the U.S. House Oversight and Reform Committee is Set to Hold a Hearing to Investigate Abuses by the Pharmaceutical Industry WASHINGTON D.C. – Recently, the Initiative for Medicines, Access & Knowledge (I-MAK) released a report as part of its “Overpatented, Overpriced” series on the cancer drug Keytruda, highlighting the underhanded tactics used by […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System. Part V: IPR & Ulcerative Colitis – Balancing Innovation and Competition Read the full story below: CAPA examined how the IPR process struck down a patent relating to the […]

Continue Reading

Part V: IPR & Ulcerative Colitis – Balancing Innovation and Competition Over the last year, the coronavirus pandemic has caused financial hardships for millions of Americans and our federal government continues to face unprecedented debt.  As recovery efforts are underway, the issue of skyrocketing prescription drug costs remains more prevalent than ever.  A major contributing […]

Continue Reading